LegoChem Biosciences focuses on innovative drug development through its proprietary technologies, primarily ConjuALL and LigaChemistry. The ConjuALL platform represents a next-generation approach to antibody-drug conjugates (ADCs), addressing limitations of existing ADC technologies by enhancing conjugation methods, linker stability, and payload efficacy. This platform allows for the creation of highly pure single substances, stable linkers that release toxins specifically within cancer cells, and improved cytotoxicity, thereby increasing the selectivity and effectiveness of cancer treatments. The company is actively developing a diverse pipeline of ADCs and other therapeutics, including immuno-oncology agents and antibiotics, leveraging these advanced technologies.

LigaChemistry, another cornerstone of LegoChem's R&D, facilitates the development of small molecule-based drugs by connecting functional chemical structures to drug scaffolds, enhancing their therapeutic potential. This technology supports the creation of various drug candidates, including anti-infectives and anti-fibrotic agents, by ensuring that the new compounds maintain drug-like properties. Together, ConjuALL and LigaChemistry enable LegoChem Biosciences to build a robust pipeline of innovative therapies aimed at addressing unmet medical needs in oncology and beyond, positioning the company as a significant player in the global biopharmaceutical landscape.

South Korea

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

LegoChem Biosciences

Company Details